|
28 Jul 2019 |
Kodiak Sciences Announces Positive Interim Data from Ongoing Phase 1b Clinical Study of KSI-301, a Novel Anti-VEGF Antibody Biopolymer Conjugate for Treatment of Wet AMD, Diabetic Eye Disease, and Retinal Vein Occlusion, at the American Society of Retina
|
|
26 Jul 2019 |
Theratechnologies Receives Positive Recommendation From the CHMP for Trogarzo® in the European Union
|
|
26 Jul 2019 |
Novartis receives positive CHMP opinion for Lucentis® treatment in preterm infants with retinopathy of prematurity (ROP), a disease causing visual impairment and blindness
|
|
26 Jul 2019 |
Roche receives CHMP positive opinion for new Tecentriq-based combination therapy as an initial treatment for most common form of advanced lung cancer
|
|
26 Jul 2019 |
CHMP recommends EU approval of Roche’s Tecentriq in combination with chemotherapy as an initial treatment of adults with extensive-stage small cell lung cancer
|
|
26 Jul 2019 |
Janssen Receives CHMP Positive Opinion for Stelara® (ustekinumab) Recommending Approval for the Treatment of Moderately to Severely Active Ulcerative Colitis in the EU
|
|
26 Jul 2019 |
Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone for Treatment of Patients with Relapsed and Refractory Multiple Myeloma
|
|
25 Jul 2019 |
Bristol-Myers Squibb Provides Update on Part 2 of CheckMate -227
|
|
25 Jul 2019 |
Bristol-Myers Squibb Announces CheckMate -227 Part 1a Meets Co-Primary Endpoint of Overall Survival
|
|
24 Jul 2019 |
Jounce Therapeutics Announces Update on Strategic Collaboration with Celgene Corporation
|
|
24 Jul 2019 |
FDA Approves Samsung Bioepis' HADLIMA™ (adalimumab-bwwd)
|
|
24 Jul 2019 |
FDA Approves Pfizer’s Biosimilar, RUXIENCE™ (rituximab-pvvr), for Certain Cancers and Autoimmune Conditions
|
|
23 Jul 2019 |
FibroGen Announces First Patient Dosed in ZEPHYRUS, a Phase 3 Clinical Trial of Pamrevlumab for the Treatment of Patients with Idiopathic Pulmonary Fibrosis
|
|
23 Jul 2019 |
Resolve Therapeutics Announces Completion of Enrollment for Phase 2a Study of RSLV-132 for the Treatment of Lupus
|
|
23 Jul 2019 |
IMFINZI® (durvalumab) US Label Updated With Overall Survival Data in Unresectable, Stage III Non-small Cell Lung Cancer
|
|
22 Jul 2019 |
Investigational Subcutaneous Formulation of Vedolizumab Meets Primary Endpoint in Achieving Clinical Remission at Week 52 in Patients with Moderately to Severely Active Crohn's Disease
|
|
22 Jul 2019 |
Sandoz announces first patient enrolled in clinical study for proposed biosimilar denosumab in osteoporosis
|
|
21 Jul 2019 |
Janssen Seeks EMA Approval for Novel Subcutaneous Formulation of DARZALEX® (daratumumab)
|
|
19 Jul 2019 |
EMA Accepts Samsung Bioepis’ MAA for SB8 Bevacizumab Biosimilar Candidate
|
|
19 Jul 2019 |
Eisai Presented Data Showing Quantification of Tau Microtubule Binding Region at AAIC 2019
|
|
18 Jul 2019 |
MacroGenics Provides Update on Flotetuzumab Program in Acute Myeloid Leukemia
|
|
17 Jul 2019 |
Halozyme Announces First Clinical Dosing In argenx's Phase 1 Trial Of Efgartigimod (ARGX-113) With ENHANZE® Drug Delivery Technology
|
|
17 Jul 2019 |
Orum Therapeutics Announces $30 Million Series B Financing to Advance Cell-Penetrating, Cell-Specific Antibody Technology for Novel Therapeutics
|
|
16 Jul 2019 |
Outlook Therapeutics Doses First Patient in the Second Phase 3 Clinical Trial for ONS-5010 in Wet AMD
|
|
16 Jul 2019 |
Seattle Genetics and Astellas Announce Submission of Biologics License Application to FDA for Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer
|
